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Abstract
Background: Despite improvements in treatment success rates for tuberculosis (TB), current six-month regimen
duration remains a challenge for many National TB Programmes, health systems, and patients. There is increasing
investment in the development of shortened regimens with a number of candidates in phase 3 trials.
Methods: We developed an individual-based decision analytic model to assess the cost-effectiveness of a hypothetical
four-month regimen for first-line treatment of TB, assuming non-inferiority to current regimens of six-month duration.
The model was populated using extensive, empirically-collected data to estimate the economic impact on both health
systems and patients of regimen shortening for first-line TB treatment in South Africa, Brazil, Bangladesh, and Tanzania.
We explicitly considered ‘real world’ constraints such as sub-optimal guideline adherence.
Results: From a societal perspective, a shortened regimen, priced at USD1 per day, could be a cost-saving option in
South Africa, Brazil, and Tanzania, but would not be cost-effective in Bangladesh when compared to one gross
domestic product (GDP) per capita. Incorporating ‘real world’ constraints reduces cost-effectiveness. Patient-incurred
costs could be reduced in all settings. From a health service perspective, increased drug costs need to be balanced
against decreased delivery costs. The new regimen would remain a cost-effective option, when compared to each
countries’ GDP per capita, even if new drugs cost up to USD7.5 and USD53.8 per day in South Africa and Brazil; this
threshold was above USD1 in Tanzania and under USD1 in Bangladesh.
Conclusion: Reducing the duration of first-line TB treatment has the potential for substantial economic gains
from a patient perspective. The potential economic gains for health services may also be important, but will
be context-specific and dependent on the appropriate pricing of any new regimen.
Keywords: Tuberculosis, Cost-effectiveness, Economic evaluation, New technologies
Background
Globally, despite advances in diagnostic technologies
and treatment success rates, tuberculosis (TB) remains a
substantial health problem [1]. A major challenge faced
by National TB Programs and patients is the length and
complexity of existing regimens. New shortened regi-
mens have potential advantages: improving outcomes
through increasing adherence; decreasing time to cure;
reducing costs incurred by patients; and reducing treat-
ment delivery costs incurred by health systems [2, 3].
These potential health and economic gains have moti-
vated increasing investments in new regimens in recent
years [4–6]. Although recent trials of new TB regimens,
such as four-month moxifloxacin-based regimens, have
so far proved unsuccessful [4], larger-scale trials including
new drugs are ongoing [7]. Understanding the potential
benefits and costs of introducing new TB regimens in
different epidemiological and health system contexts
is therefore critical in the context of the post-2015
global TB Targets.
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Previous efforts to quantify the economic and health
impact of shortened regimens have been limited; and
these efforts have focused on general analyses that are
not specific to any particular setting. While such studies
can identify key drivers of cost-effectiveness at a general
level, further work is required to characterize the cost-
effectiveness of new TB regimens at country level [8–11].
Importantly, none of the previous studies were parameter-
ized with locally-collected data; or reflect the influence of
health system constraints. Incorporating sound empirical
data on health service costs is critical, given that one of
the central aims of introducing new shortened first-line
regimens is to achieve a reduction in health system
burden from TB treatment. Moreover, while previous
studies have included estimates of provider costs, none
of these studies have considered the potential cost
savings to patients. The potential benefits in terms of
patient costs are important in the light of the post-2015
global TB target of ensuring that no-one suffers cata-
strophic expenditures from TB, in the context of Universal
Health Coverage.
We explore the cost and cost-effectiveness of introdu-
cing a new shortened TB regimen in four countries. We
use primary data on both patient and provider incurred
costs; and incorporate data on local patterns of TB treat-
ment delivery in our estimates. The aim is to guide fur-
ther development and in-country adoption of shortened
first-line TB regimens.
Methods
Model
We used a decision analytic model to compare the cost-
effectiveness of a hypothetical four-month regimen to
the existing standard of care, a six-month regimen for
first-line treatment of TB. Our primary outcomes were
the incremental cost per disability-adjusted life-year
(DALY) averted, and incremental average total, health
service and patient incurred costs. Our population was a
cohort 10,000 individuals with newly diagnosed pulmon-
ary TB and no previous treatment history, characterised
for four settings, South Africa, Bangladesh, Brazil and
Tanzania (Additional file 1: Table S1). The model de-
fined each individual patient in the cohort by smear sta-
tus (positive or negative), HIV (positive or negative),
antiretroviral treatment (ART) (treated or not treated),
and resistance profile (pan-sensitive or resistant to at
least rifampicin) to reflect the multi-drug resistant TB
(MDR-TB) burden in each country.
The treatment approach was informed by national guide-
lines, which are laid out in table S2 (Additional file 1). At
the end of each month, patients could either continue on
or complete treatment, be lost to follow-up (default), die,
or (in the final month of treatment) fail. Loss to follow-up
is defined as a patient whose treatment is interrupted for
two consecutive months [12]. After loss to follow-up,
we assumed patients may re-enter care, thereafter clas-
sified as previously treated. The duration of treatment
before default determined the treatment algorithm to
be followed once the patient returned to care. The
probability of cure after default also depended on the
duration of treatment completed before defaulting as
per the literature of shorter-course regimens [13]. Pa-
tients stopping treatment in the first two months were
assumed to receive no benefit from the treatment and
have a probability of cure equivalent to the probability
of spontaneous recovery. Thereafter, patients stopping
treatment received partial benefit from the treatment
and have a probability of cure proportional to the
length of treatment completed [13].
Treatment failure was defined as a smear positive re-
sult at five months or later during treatment [12]. After
treatment failure, we assumed that patients complete
either a second round of treatment (standard first line in
South Africa and Brazil or one course of retreatment in
Bangladesh and Tanzania, where retreatment regimens
are available) or, where they have been diagnosed as
rifampicin-resistant after drug susceptibility testing
(DST), one course of MDR-TB treatment. If they failed
the second round of treatment, they were considered
not to receive additional treatment, and become chronic
TB cases until death. Cases of relapse (a new episode of
TB after a period of no TB) were excluded [12].
The model was built using TreeAge software. Several
schematics of the model are presented in the Additional
file 1: Figure S1 to Figure S3, while the main parameter
values used are presented in Table 1.
Intervention
We modelled a non-inferior four-month new regimen
compared to the current six-month regimen, on the as-
sumption that non-inferiority would be the minimal
aim of new trials. Non-inferiority refers to the efficacy
of the regimen. Given this conservative assumption, the
potential impact of the new shortened regimen on
health outcomes results from an increase in effective-
ness due to a higher probability of patients completing
a shortened treatment regimen and a higher probability
of cure if patients stop treatment early after taking at
least two months of the shortened regimen. Introduc-
tion of the new regimen into practice was set to follow
national TB treatment guidelines with regards to DST
algorithms, eligibility for first-line therapy, monitoring,
standardised MDR treatment, directly observed ther-
apy (DOT), and ART eligibility for HIV/TB patients
(Additional file 1: Table S3). Where DST was avail-
able, we assumed that a case resistant to rifampicin
will not be eligible for either the new or current first-
line treatment regimen.
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Table 1 Parameters
Parameter, value [range] South Africa Brazil Bangladesh Tanzania Reference
Population distribution
Smear-positivity: HIV-negative, HIV-positive no ART, HIV-positive ART 0.69, 0.35, 0.45 [29] [30]
MDR prevalence, among new patients 1.8% 1.4% 1.4% 1.1% [1, 31, 32]
Prevalence of HIV in TB patients 62% 17% 3% 37% [1, 33, 34]
Diagnosis of TB
TB diagnosis, sensitivity, smear, HIV negative 0.72 [0.62–0.82] [29, 35]
TB diagnosis, sensitivity, smear, HIV positive 0.47 [0.51–0.43] [29, 35]
TB diagnosis, sensitivity, GeneXpert, smear positive 0.98 [0.97–0.99] [36]
TB diagnosis, sensitivity, GeneXpert, smear negative 0.68 [0.59–0.75] [36]
TB diagnosis, specificity, GeneXpert, all 0.98 [0.97–0.99] [36]
TB diagnosis, specificity, smear, all 1 assumption
RIF-resistance diagnosis, sensitivity, GeneXpert, all 0.94 [0.87–0.97] [36]
RIF-resistance diagnosis, specificity, GeneXpert, all 0.98 [0.97–0.99] [36]
Outcomes (first line treatment)
Pr mortality:
Pan-sensitive, HIV negative 0.03 [0.02–0.03] [37]
MDR, HIV negative 0.11 [0.08–0.13] [37]
Pan-sensitive, HIV positive, ART 0.07 [0.05–0.09] [38]
Pan-sensitive, HIV positive, no ART 0.33 [0.30–0.43] [38]
MDR, HIV positive, ART 0.11 [0.10–0.21] [38, 39]
MDR, HIV positive, no ART 0.85 [0.72–0.98] [39]
Pr cure, if treatment completed:
Pan-sensitive 0.97 [0.95–0.98] [13]
MDR 0.50 [0.40–0.55] [37]
Pr cure, if less than 2 months treatment completed
HIV negative, smear negative 0.20 [0.15–0.25] [40–42]
HIV negative, smear positive 0.30 [0.20–0.40] [40–42]
HIV positive, smear neg/pos, no ART 0 [0–0.05] [40–42]
HIV positive, smear negative, ART 0.10 [0.05–0.15] [40–42]
HIV positive, smear positive, ART 0.05 [0–0.10] [40–42]
Pr cure, if default at (standard 6mo regimen):
2–3 months, pan-sensitive 0.68 [0.50–0.80] [43]
2–3 months, MDR 0.35 [0.21–0.45] [43]
4–5 months, pan-sensitive 0.86 [0.70–0.89] [44, 45]
4–5 months, MDR 0.48 [0.29–0.51] [44, 45]
Pr cure, if default at (new 4mo regimen):
2–3 months, pan-sensitive 0.74 [0.57–0.83] Assumption
2–3 months, MDR 0.38 [0.23–0.47] Assumption
Outcomes (second round of treatment)
Pr patients returning to care after default 0.21 [0.10–0.70] [46]
Pr patients staying in care after failure 0.60 [0.40–0.80] Assumption
Pr mortality
HIV negative/positive ART, pan-sensitive 0.06 [0.04–0.07] [37]
HIV negative/positive ART, MDR 0.15 [0.10–0.20] [37]
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Costs
Costs related to TB treatment were estimated from a soci-
etal perspective in South Africa, Bangladesh, Brazil, and
Tanzania, using extensive primary costing surveys. All cost
estimates are presented in 2013 USD [14, 15]. Summary
costs are presented in Table 2; full details on the costing
methodology can be found in publications elsewhere
[3, 16–19] and summarized in table S4, while detailed unit
costs are presented in Additional file 1: Table S5.
Health service-related costs
We included service provider costs for all countries and,
where feasible, we also included costs incurred above
site level, such as monitoring and evaluation and coord-
ination costs. In South Africa, we sourced unit cost data
from the “Xpert for TB: Evaluating a New Diagnostic”
(XTEND) trial. Data from this trial were collected from
eight clinics, 20 laboratories and three MDR treatment
sites [18]. In Bangladesh, Tanzania, and Brazil, we con-
ducted health facility costing studies in nine, six, and ten
sites respectively. We used a systematic review of previous
costing studies to support our estimates, describe param-
eter bounds and assess representativeness, and, in the case
of Tanzania (as we were not able to cost from any
community-based DOT activities for feasibility reasons),
community-based TB-specific costs were also sourced
from the literature [20]. Other costs, such as MDR-TB
and ART treatment costs, were sourced from the litera-
ture [21–24]. We conducted our primary analysis using a
new regimen cost of USD1 per day, in line with previous
studies [8].
Patient-related costs
Patient data from Bangladesh and Tanzania on direct
and indirect costs were sourced from a recent study [3].
In South Africa, XTEND study’s patient cost data were
used [17]. In Brazil, we interviewed 126 patients from
ten facilities located between the municipality of Rio and
peri-urban areas ensuring a mix of wealthier and poorer
areas [16]. A review of previous costing studies was used
to assess the representativeness and explore uncertainty;
and to source information on patient costs for ART in
HIV co-infected patients and MDR-TB patients in all
countries, except South Africa.
Analysis
We calculated DALYs averted from patients being cured
using the standard formula [25]. Further details on
DALY assumptions can be found in Additional file 1:
Table S6. We then modelled the intervention using a
two-stage approach. Firstly, we modelled the full imple-
mentation of the TB treatment guidelines (including full
adherence to ART treatment guidelines and MDR treat-
ment coverage) against a locally-parameterised context
(epidemiological and study population characteristics).
Default rate in this scenario has been set to be at a pro-
grammatic minimum of 1–2%, as observed in the recent
trial for shortened first-line regimens [4].
In a second stage, we explored the sensitivity of our
results to a scenario reflecting current practice, where
providers did not adhere to the guidelines and patients
have a higher rate of default, reflecting ‘real world’ con-
ditions. Default in this scenario is equal to the one re-
ported by countries in the 2014 Global TB report [1].
Table 1 Parameters (Continued)
HIV positive no ART, pan-sensitive 0.33 [0.30–0.43] [38]
HIV positive no ART, MDR 0.85 [0.72–0.98] [39]
MDR treatment and long term outcomes
Pr cure, MDR treatment (including default) 0.65–0.80 [47]
Mortality during MDR treatment 0.10 [48]
Pr long term mortality (chronic TB patient or
default patient if no return to care)
0.75 [0.50–0.99] [48]
Self-cure among chronic TB patients 0.01 [48]
DALYs averted (discounted at 0.03/year)
HIV negative, smear negative 12.5 [11.3–13.8] 19.3 [17.4–21.3] 15.3 [13.7–16.8] 14.2 [12.8–15.7] Additional file 1
HIV negative, smear positive 15.2 [13.7–16.7] 22.0 [19.8–24.2] 17.9 [16.1–19.7] 16.9 [15.2–18.6] Additional file 1
HIV positive, smear negative, no ART 1.8 [1.6–2.0] 1.8 [1.6–2.0] 1.8 [1.6–2.0] 1.8 [1.6–2.0] Additional file 1
HIV positive, smear positive, no ART 2.0 [1.8–2.2] 2.0 [1.8–2.2] 2.0 [1.8–2.2] 2.0 [1.8–2.2] Additional file 1
HIV positive, smear negative, ART 9.9 [8.9–10.9] 9.9 [8.9–10.9] 9.9 [8.9–10.9] 9.9 [8.9–10.9] Additional file 1
HIV positive, smear positive, ART 10.1 [9.1–11.1] 10.1 [9.1–11.1] 10.1 [9.1–11.1] 10.1 [9.1–11.1] Additional file 1
HIV human immunodeficiency virus, TB tuberculosis, ART antiretroviral treatment, MDR multidrug resistant, Pr probability
Parameters with one value are included in the model as point estimates; parameters with a value and a range were included in the model as triangular
distributions; parameters with only a range of two values were included in the model as a uniform distribution
Gomez et al. BMC Infectious Diseases  (2016) 16:726 Page 4 of 13
We considered non-adherence of two types: non-
adherence to the coverage of complementary services
(ART and MDR-TB treatment), which affects survival
once treatment is completed, and non-adherence to
first-line treatment monitoring (directly observed ther-
apy, DOT) by providers. With respect to the former we
applied the current coverage levels for ART and MDR-
TB treatment; with respect to the latter we allowed the
unit costs (and patient costs) of both the standard of
care and the new regimen to reflect current levels of
DOT. Table 3 shows the coverage levels by scenario.
We used a probabilistic sensitivity analysis (Monte
Carlo simulation) to randomly sample parameters from
distributions (defined in Table 1), conducting 1,000
Table 2 Costs
South Africa Brazil Bangladesh Tanzania Reference
a. Guidelines
Healthcare provider costs
First-line treatment, IP, 1mo (excl drugs) 200 (152–230) 333 (117–479) 17 (12–21) 65 (24–106) [16, 18, 19]
First-line treatment, CP, 1mo (excl drugs) 54 (41–62) 333 (117–479) 11 (7–15) 16 (7–24) [16, 18, 19]
Drugs, first-line, IP, 1mo 16 7 (6–9) 7 (6–8) 6 [16, 18–20]
Drugs, first-line, CP, 1mo 19 4 (3–6) 3 (3–3) 2 [16, 18–20]
Retreatment: all n/a n/a 213 (160–266) 430 (310–549) [16, 18, 19]
MDR treatment: all 10,215 (8,619–24,580) 5,223 (4,800–5,348) 4,262 (3,836–4,688) 2,507 (2,454–2,561) [16, 18, 19]
ART cost in year 1 1,128 (1,117–1,139) 5,875 (5,288–6,463)a 800 (720–880) 315 (283–346) [21, 22, 49–52]
ART cost per year (after year 1) 639 (575–703) 600 (540–660) 277 (249–304) [21, 22, 49–52]
Patient costs
First-line treatment, IP, 1mo 149 (87–164) 40 (8–131) 314 (283–346) 186 (167–204) [3, 16, 17]
First-line treatment, CP, 1mo 117 (34–129) 40 (8–131) 31 (28–34) 44 (40–48) [3, 16, 17]
Retreatment: all n/a n/a 135 (121–148) 354 (319–390) [3, 16, 17]
MDR treatment: all 3,319 (2,987–3,650) 280 (102–1142) 213 (192–234) 454 (409–499) [3, 16, 17]
ART cost in year 1 106 (96–117) 23 (4–43) 8 (7–8) 24 (22–26) [53]
ART cost per year (after year 1) 85 (77–93) 9 (2–17) 3 (3–3) 10 (9–11) [53]
Cost per visit to healthcare facility 8 (7–9) 5 (1–9) 2 (1–2) 5 (4–5) [3, 16, 17]
b. Current
Healthcare provider costs
First-line treatment, IP, 1mo (excl drugs) 61 (40–96) 133 (59–285) 17 (12–21) 35 (24–45) [16, 18, 19]
First-line treatment, CP, 1mo (excl drugs) 16 (11–26) 133 (59–285) 11 (8–15) 16 (7–24) [16, 18, 19]
Drugs, first-line, IP, 1mo 16 7 (6–9) 7 (6–8) 6 [16, 18–20]
Drugs, first-line, IP, 1mo 19 4 (3–6) 3 (3–3) 2 [16, 18–20]
Retreatment: all n/a n/a 213 (160–266) 429 (310–549) [16, 18, 19]
MDR treatment: all 10,215 (8,619–24,580) 5,223 (4,800–5,348) 4,262 (3,836–4,688) 2,507 (2,454–2,561) [16, 18, 19]
ART cost in year 1 1,128 (1,117–1,139) 5,875 (5,288–6,463)a 800 (720–880) 315 (283–346) [21, 22, 49–52]
ART cost per year (after year 1) 639 (575–703) 600 (540–660) 277 (249–304) [21, 22, 49–52]
Patient costs
First-line treatment, IP, 1mo 60 (35–66) 40 (8–131) 314 (283–346) 144 (139–149) [3, 16, 17]
First-line treatment, CP, 1mo 27 (8–30) 40 (8–131) 31 (28–34) 41 (37–44) [3, 16, 17]
Retreatment: all n/a n/a 135 (121–148) 354 (319–390) [3, 16, 17]
MDR treatment: all 3,319 (2,987–3,650) 280 (102–1,142) 213 (192–234) 454 (409–499) [3, 16, 17]
ART cost in year 1 106 (96–117) 23 (4–43) 8 (7–8) 24 (22–26) [53]
ART cost per year (after year 1) 85 (77–94) 9 (2–17) 3 (3–3) 10 (9–11) [53]
Cost per visit to healthcare facility 8 (7–9) 5 (1–9) 2 (1–2) 5 (4–5) [3, 16, 17]
IP intensive phase, CP continuation phase, mo month, excl excluding, ART antiretroviral treatment, MDR multidrug resistant, DST drug resistance testing
aAverage cost per year
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simulations each of random populations of 10,000 indi-
viduals. We report the standard deviations and 95%
uncertainty ranges (2.5th and 97.5th percentiles). We ex-
plored the main drivers of uncertainty in our estimates
in a series of one-way sensitivity analyses by varying
each of the following variables over widest plausible
ranges sourced from the literature: default rate during
treatment, mortality during first-line treatment and after
default, prevalence of MDR, no cure if treatment was
partially completed, probability of returning to care after
default, length of survival if on ART, and discount rate.
Finally, given the uncertainty around drug prices, we
conducted a threshold analysis to examine the price for
which the incremental cost-effectiveness ratio (ICER) of
new TB treatment regimens crosses selected willingness-to-
pay (WTP) thresholds. WTP was defined as a quarter, half,
or one times the country-specific gross domestic product
per capita for the year 2013, to acknowledge possible lim-
ited discretionary resources available, and thus effective op-
portunity costs, within health services in low and middle
income countries. Future costs and health gains during the
patient’s lifetime were discounted at a rate of 3% per year.
We conducted and present this study following good
reporting practices from published standards: the
CHEERS statement (Additional file 2: Checklist), and
the Bill and Melinda Gates Foundation’s Methods for
Economic Evaluation consensus [26, 27].
Results
Figure 1 shows the cost savings in TB-related costs per
new TB patient by country, scenario, and payer. Shortening
the treatment regimen from six to four months was
projected to reduce patient costs in all settings. These sav-
ings are estimated to be highest in Brazil (-30%), then
South Africa (-25%) and lowest in Bangladesh (-5%), where
the delivery of TB services at the community level mini-
mizes patient costs [3]. From a health service perspective,
there is a trade-off between increased drug costs and de-
creased delivery costs. In settings where existing drug and
delivery costs were low, the new regimen (assumed drug
price of USD1 per day) increased overall health service
costs (USD75 in Bangladesh (60% increase), USD72 in
Tanzania, (32% increase)). In contrast, where existing drug
and delivery costs are higher, a shorter-course regimen was
cost saving (-USD20 in South Africa, 1 · 7% reduction; and
-USD463 in Brazil, 24% reduction) (Fig. 1).
When taking into account ‘real world’ provision of TB
treatment, these cost savings were substantially lower in
South Africa and Brazil. In this case the shortened regi-
men is no longer cost saving, but results in an 8.4% in-
crease in cost of first-line TB treatment in South Africa,
while cost savings are reduced to USD160 in Brazil.
Examining the costs related to HIV, we found that the
introduction of a new shortened first-line regimen for
TB does not substantially affect the incremental costs
related to ART (Additional file 1: Table S7).
Although modelling non-inferiority, we observe some
benefit for the patient cohort, in terms of mortality reduc-
tion and treatment completion (see Additional file 1:
Table S8) from a reduction in default. These benefits
are larger in high default settings; and in our ‘real
world’ analysis. However, this positive effect on mor-
tality and DALYs averted is modest, across all scenar-
ios and countries (Table 4).
Table 3 Scenario parameters: coverage levels for GeneXpert, MDR treatment and ART in HIV co-infected individuals
South Africa Brazil Bangladesh Tanzania reference
All scenarios
GeneXpert coverage in new patients 100% 100% 0% 0% assumption
GeneXpert coverage in previously treated 100% 100% 100% 100% assumption
Guidelines
ART if HIV/TB 100% 100% 100% 100% [54–61]
MDR treatment 100% 100% 100% 100% [56, 59, 60, 62]
Default rate 1–2% 1–2% 1–2% 1–2% [4]
Current
ART if HIV/TB 66% 54.7% 100% 73% [1, 63]
MDR treatment 60% 44.5% 15.4% 12.3% [1, 64]
Default rate 8% [6–10] 21% [19–23] 2% [1.8–2.2] 3% [2–4] [1]
ART antiretroviral treatment, HIV human immunodeficiency virus, TB tuberculosis, MDR multidrug resistant. Current coverage of ART in HIV/TB co-infection as reported
in Global TB report 2014 [1], except for Brazil where this is not reported. For Brazil, we calculated the coverage of ART in HIV/TB co-infection as 84% ART coverage in
general HIV patients [63] of 65% TB patients knowing their HIV status. Current coverage of MDR TB treatment was calculated from the Global TB report 2014 [1] from
the prevalence of MDR among new and retreatment patients times the number of notifications for new and retreatment patients respectively. This was considered the
denominator (total number of MDR patients). The numerator (patients on MDR treatment) was sourced from the Global TB report 2014. For South Africa, we added the
estimated current MDR coverage levels as per the National Department of Health [64]. Note: parameters with one value are included in the model as point estimates;
parameters with a value and a range were included in the model as triangular distributions; parameters with only a range of two values were included in the model
as a uniform distribution
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Cost-effectiveness varies by setting when we assume the
drugs for the shorter regimen to be priced at USD1 per
day (Table 4). In South Africa, only the current scenario
was not estimated to be cost saving but remained a cost-
effective choice (mean USD13.6 per DALY averted). In
Tanzania, new shortened regimens in the guideline sce-
nario might be cost saving, but when ‘real world’ consider-
ations are taken into account, extra investment is needed.
However, this extra investment was cost-effective (mean
USD161 per DALY averted). In contrast, in Bangladesh,
across both scenarios, this investment was not cost-
effective when compared to one GDP per capita as a
WTP threshold (mean USD1,472 and 1,220 per DALY
averted in guidelines and current scenarios, respectively),
reflecting the trade-off between the higher drug prices
assumed for the new regimen and low service delivery
costs. In one-way sensitivity analyses, our conclusions
were stable to most of the assumptions made (Fig. 2).
Cost-effectiveness was most sensitive to existing health
service costs for treatment delivery and default rates. In
addition to these, in Brazil and South Africa (Fig. 2a and b),
a higher prevalence of MDR resulted in an increase in cost
savings, while a high probability of returning to care after
default reduced the incremental benefits observed. In
Bangladesh (Fig. 2c), a higher prevalence in MDR changed
from an assessment of the new regimen not being cost-
effective to being cost-saving. The new shortened regimen
remained cost-effective in Tanzania under all analyses.
Using a threshold analysis (Fig. 3), we estimated that
in settings with low treatment delivery costs (Bangladesh
and Tanzania) the threshold price for achieving cost-
effectiveness is approximately USD1 per day and it re-
mains at this level if different assumptions of adherence
to guidelines are made. In settings with higher treatment
delivery costs (Brazil and South Africa), the threshold
price varies substantially depending on how closely
current practice adheres to guidelines. In general, the
threshold drug price are reduced if treatment guidelines
are totally adhered to (mainly due to a higher cost in
health service delivery and better effect).
Discussion
We present a four-country economic evaluation of the
introduction of a new hypothetical four-month TB
Fig. 1 Differences in mean TB-related costs per new TB patient between the new 4 four-month regimen and the six-month regiment, by country,
scenario, and payer. Difference of means – negative number refers to cost savings of introducing a shortened regimen compared to baseline
(standard treatment). Health services costs are calculated assuming a drug price for the shortened regime of 1USD. These costs do not include
ART-related costs. We define the societal perspective as the sum of health service and patient (and their households) perspectives. In the case of
South Africa (current scenario) and Tanzania (current and guidelines scenario), the societal perspective costs are very close to cost neutral
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regimen compared to the current six-month regimen.
The cost-effectiveness of the new shortened regimen for
first-line TB treatment varies substantially by setting and
current treatment practice. We find that a new non-
inferior shortened regimen costing USD1 a day would
likely be cost-saving in Brazil, South Africa, and
Tanzania, but not in Bangladesh, assuming full adher-
ence to treatment guidelines. Potential health service-
related cost savings are modest and are lower when ‘real
world’ treatment practice is taken into account. Patient
incurred cost savings are substantial in all settings, espe-
cially when services are facility-based rather than
Table 4 DALYs averted per country and scenario and incremental cost-effectiveness ratios (societal perspective), if drug price is
1USD per day
Guidelines Current
South Africa
Current 6mo Rx DALY averted, mean (SD) 9.97 (0.23) 8.26 (0.18)
DALY averted, median (2.5–97.5) 9.97 (9.52–10.42) 8.26 (7.92–8.61)
New 4mo Rx DALY averted, mean (SD) 10.0 (0.23) 8.37 (0.18)
DALY averted, median (2.5–97.5) 9.99 (9.55–10.43) 8.37 (8.04–8.72)
mean difference (%) 0.02 (0.07) 0.11 (0.03)
ICER, median (2.5–97.5) CS (CS-26,065) 16.9 (CS-897)
ICER, calculated mean CS 13.6
GDP per capita 6,618
Brazil
Current 6mo Rx DALY averted, mean (SD) 16.50 (0.51) 14.68 (0.51)
DALY averted, median (2.5–97.5) 16.52 (15.54–17.48) 14.67 (13.74–15.65)
New 4mo Rx DALY averted, mean (SD) 16.54 (0.51) 15.18 (0.51)
DALY averted, median (2.5–97.5) 16.56 (15.55–17.54) 15.16 (14.25–16.16)
mean difference (%) 0.04 (0.06) 0.50 (0.08)
ICER, median (2.5–97.5) CS (CS-116,251) CS (CS-362)
ICER, calculated mean CS CS
GDP per capita 11,208
Bangladesh
Current 6mo Rx DALY averted, mean (SD) 16.19 (0.53) 16.17 (0.51)
DALY averted, median (2.5–97.5) 16.20 (15.20–17.21) 16.16 (15.17–17.15)
New 4mo Rx DALY averted, mean (SD) 16.21 (0.53) 16.20 (0.51)
DALY averted, median (2.5–97.5) 16.22 (15.19–17.24) 16.18 (15.19–17.15)
mean difference (%) 0.02 (0.06) 0.02 (0.06)
ICER, median (2.5–97.5) 164 (CS-9,075) 129 (CS-8,824)
ICER, calculated mean 1,472 1,220
GDP per capita 829
Tanzania
Current 6mo Rx DALY averted, mean (SD) 13.66 (0.36) 12.97 (0.36)
DALY averted, median (2.5–97.5) 13.66 (12.98–14.35) 12.96 (12.31–13.65)
New 4mo Rx DALY averted, mean (SD) 13.68 (0.36) 13.00 (0.36)
DALY averted, median (2.5–97.5) 13.67 (12.99–14.36) 12.99 (12.32–13.70)
mean difference (%) 0.02 (0.04) 0.03 (0.05)
ICER, median (2.5–97.5) CS (CS-12,252) 39 (CS-3,937)
ICER, calculated mean CS 161
GDP per capita 695
Mo months, Rx treatment, DALY disability-adjusted life years, SD standard deviation, ICER incremental cost effectiveness ration, CS cost saving, GDP per capita gross
domestic product per capita
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community-based. Individual health benefits are positive
but modest.
Our findings are line with other recent studies that,
contrary to earlier efforts, suggest that the health benefits
(including population level) of regimen shortening are
likely to be limited [11]. However, in light of the post-
2015 TB control strategy that aims for ‘no affected
families facing catastrophic costs due to TB’ by 2025,
we highlight the importance of the economic benefits
of regimen shortening to patients. For example, in
South Africa, 37% of TB patients were found to incur
catastrophic costs; [17] and thus reducing costs by 25%
may prevent considerable numbers falling into poverty
because of contracting TB.
The difference in health service costs between settings
highlights the importance of accounting for setting-specific
resource use, health service and demand constraints.
Previous efforts, have assumed that any health service
costs could be substantial and if usefully channeled
back into other TB services – may have substantial
impact [9]. Our findings are more modest and variable,
but it should be noted that any savings remain critical,
in the current situation where most current TB control
programmes are substantially underfunded [1]. Para-
doxically, incorporating a ‘real world’ perspective re-
sults in new regimens having lower economic benefits.
However, one of the reasons for poor guideline adher-
ence may be substantial constraints to TB treatment
delivery, and so even freeing up modest resources in
these settings may be important to improve TB treat-
ment delivery more generally.
Drug prices have an important impact on our findings.
However, to date, there is no public information on what
the future cost of such a regimen would be or whether it
a) South Africa
b) brazil
c) Bangladesh d) Tanzania
Fig. 2 One-way sensitivity analysis by country. a South Africa (current scenario, drug price 1USD per day). We show variations in incremental
cost-effectiveness ratio (ICER) to analyse the influence of different assumptions on our conclusions of cost-effectiveness. High/low refers to a
higher/lower value of the parameter being considered compared to the baseline value. The x-axis shows the change in the ICER where 0 represents
no change (ie baseline ICER). The double red line represents the change in ICER when the result is cost saving (i.e. negative ICERs). Negative ICERs are
not at scale and this is indicated by a double slash. b Brazil (guidelines current, drug price 1USD per day). We show variations in incremental cost and
incremental effect as opposed to changes in incremental cost-effectiveness ratio (ICER) because for Brazil, the ICER remains negative in this scenario
(ie cost saving). The purpose is to investigate the impact of our assumptions on two components of the ICER: incremental cost and incremental
effect. High/low refers to a higher/lower value of the parameter being considered compared to the baseline value. The x-axis shows the change
in incremental costs or incremental effects (DALYs averted) compared to the baseline result (a negative value in incremental costs means
less cost differentials, same applies to the DALYs), 0 represents no change (ie baseline). c Bangladesh (current scenario, drug price 1USD
per day). We show variations in incremental cost-effectiveness ratio (ICER) to analyse the influence of different assumptions on our conclusions
of cost-effectiveness. High/low refers to a higher/lower value of the parameter being considered compared to the baseline value. The x-axis shows the
change in the ICER where 0 represents no change (ie baseline ICER). The single red line represents the change in ICER when the result becomes
cost-effective (one GDP as willingness-to-pay threshold). The double red line represents the change in ICER when the result is cost saving
(i.e. negative ICERs). Negative ICERs are not at scale and this is indicated by a double slash. d Tanzania (current scenario, drug price 1USD
per day). We show variations in incremental cost-effectiveness ratio (ICER) to analyse the influence of different assumptions on our conclusions of
cost-effectiveness. High/low refers to a higher/lower value of the parameter being considered compared to the baseline value. The x-axis shows the
change in the ICER where 0 represents no change (ie baseline ICER)
Gomez et al. BMC Infectious Diseases  (2016) 16:726 Page 9 of 13
will vary by setting. Initial estimates of previously tested
shortened regimens priced these regimens between
USD10 and USD25 per month. We assumed a price of
USD30 to provide a conservative point estimate of drug
costs. However, as there is a high degree of uncertainty
around price, we conducted a threshold analysis. Here
we found that the threshold price per day was substan-
tially higher in those settings where treatment delivery
costs were higher (South Africa, USD10; Brazil, USD57);
this threshold was sensitive to the adherence to guidelines
assumptions. For those settings with lower treatment
delivery costs (e.g. Tanzania and Bangladesh), USD1 per
day was the maximum price for cost-effectiveness, but
this threshold is sensitive to the uncertainty observed
in effect estimates.
Our study has several limitations. We excluded bene-
fits in children or in the prevention of downstream
transmission and acquired resistance. The additional
benefits due to transmission prevented has been esti-
mated to be low in previous studies [11, 28], The bene-
fits from reductions in acquired resistance are highly
uncertain. This is in part due to lack of data on the
probability of acquiring resistance, particularly where the
precise regimen remains undefined. Once regimen profiles
become available this will be an important consideration
for further analyses. At this point, we are presenting con-
servative results, and it is possible that higher regimen
prices may be cost-effectiveness once these benefits are
taken into account. However, the additional benefits due
to transmission prevented has been estimated to be low,
while there is significant uncertainty on the effect of new
regimens on future acquired resistance trends [11, 28].
With regards to benefits due to acquired resistance
prevented, the magnitude of these benefits will depend ex-
clusively on the drug regimen being introduced and will
be an important consideration for further analyses. We
did not include programme costs of new drug introduc-
tion (i.e. system-wide costs allowing the new regimen to
be introduced, such as development of new treatment
guidance or setting up new monitoring systems) nor did
we examine the influence of alternative approaches to
treatment observation going forward. In the case of the
former, this exclusion may overestimate cost savings.
However, any introduction cost, or startup cost, would be
a one-off occurrence which would be discounted over
time. In the case of the latter, where lower cost methods
of observation are introduced in both base case and the
alternative, cost savings may also be reduced.
Conclusions
A four-month non-inferior first-line TB regimen is likely to
be cost saving or cost-effective in many country settings.
This benefit is more marked in middle income countries,
like South Africa and Brazil, where health service delivery
costs are higher. Adherence to TB treatment guidelines is
a key determinant of cost-effectiveness when considering
the introduction of shortened regimens. In low income
countries, like Tanzania and Bangladesh, drug price is likely
to be critical for cost-effectiveness. In terms of the post-
2015 global TB targets, the most notable benefit of short-
ened regimens is to reduce the economic burden on
households. In reaching these conclusions, we adopted an
approach that considers individual and health service util-
isation characteristics as well as societal costs using
country-specific information, allowing us to tailor the ana-
lysis and conclusions to specific ‘real world’ settings.
a) Guidelines scenario b) Current scenario
Fig. 3 Estimated drug price per month at which the mean ICER (new regimen vs standard) crosses a particular CE threshold by country and
scenario. a Guidelines scenario. b Current scenario. Drug price in the y-axis is the drug price at which the mean ICER crosses the WTP threshold.
GDP: gross domestic product per capita
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